Kisqali 200 mg film‑coated tablets clinical trials
7 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase I/II study to determine the safety and efficacy of Ribociclib in combination with hormone therapy and hypofractionated radiotherapy in breast cancer, with positive hormone receptors and negative HER2 status, in newly diagnosed, not immediately operable (or wishing to avoid surgery), elderly patient
This study looks at a new way to treat specific breast cancers in older women. It combines a drug called Kisqali with hormone therapy and focused radiotherapy. We want to see if this treatment is safe and effective, especially for patients who can't have or prefer to avoid surgery.
For: breast cancerFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
SAFIR 03_A ctDNA screening program in patients with HR+, HER2- metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor and a randomised phase II study comparing alpelisib combined with fulvestrant to ribociclib combined with fulvestrant, in patients with persistent targetable PIK3CA mutations.
This study looks at new ways to treat advanced breast cancer that has spread. It's for women with a specific type of hormone-positive breast cancer. Researchers are comparing two different drug combinations to see which works best at stopping the cancer from growing.
For: Metastatic Breast Cancer HR+ · HER2-France - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
This study is testing a new drug, BLU-222, for people with certain advanced cancers, including breast, ovarian, and stomach cancers. It aims to see how safe the drug is, how it moves through the body, and if it helps shrink tumors, both on its own and with other treatments.
For: HR+ Breast Cancer CCNE1 Amplification HER2-negative Breast Cancer Advanced Solid Tumor Ovarian Cancer Endometrial Cancer Gastric CancerFrance · Italy · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA
This study compares two common breast cancer medicines, Kisqali and IBRANCE, for advanced hormone receptor-positive, HER2-negative or HER2-enriched breast cancer. It looks at how well they stop the cancer from growing and aims to see if one is better than the other.
For: Patients with advanced hormone receptor-positive/HER2- negative/HER2-Enriched breast cancerSpain · Portugal - AuthorisedTherapeutic use (Phase IV)
SPatial Heterogeneity of INtratumoral drug distribution
This study looks at how breast cancer drugs spread within tumours. We're testing if letrozole, Kisqali, or anastrozole reach all parts of the tumour effectively in women with ER+ HER2- breast cancer. This helps us understand if the treatments are working as well as they could.
For: ER+ HER2- Breast cancerNetherlands - AuthorisedTherapeutic use (Phase IV)
Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6 inhibitors. "The EX-AI study"
This study looks at how exercise affects the quality of life for women with early breast cancer. These women are taking hormone treatments, sometimes with another medicine called a CDK4/6 inhibitor. The study wants to see if exercise helps with symptoms and overall well-being.
For: Early Breast CancerSpain - AuthorisedTherapeutic exploratory (Phase II)
Prevention of Ribociclib-related hepatotoxicity in breast cancer patients: a phase II, multicentre, open label, single arm trial of Silimarin.
This study looks at whether a natural product called Silymarin can help protect the liver of breast cancer patients taking a medicine called Ribociclib. It aims to see if Silymarin can reduce liver side effects, comparing it to what we know from past studies.
For: hormone receptor positive · HER2-negative breast cancerItaly